VRNA - Verona Pharma Forward P/S Multiple

veronapharma.com (VRNA) - corporate logo

The launch of an innovative COPD treatment is driving revenue growth for Verona Pharma plc (VRNA), as evidenced by the price action on the GURU.Markets chart. The forward price-to-sales valuation demonstrates that the 41.30 mark is a relevant indicator. This trend reflects management's shift toward product commercialization and a flexible development model based on the full outsourcing of manufacturing and clinical trials.

VRNA Verona Pharma: Forward Price to Sales in the range 07/04/2022 - 10/18/2025

Verona Pharma plc - analytical breakdowns and key metrics (VRNA)

- stock price and consensus target price:
Stock Quotes Verona Pharma Corp|VRNA - Price Target Chart
- market capitalization statistics:
Market Capitalization Verona Pharma Inc.|VRNA - Total Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Verona Pharma|VRNA - Accounting Value of Company|Market Value to Book Value Ratio veronapharma.com|VRNA - Company Assets
- debt and liquidity data:
Debt to Equity Verona Pharma plc|VRNA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital veronapharma.com|VRNA - Company Aggregate Debts|Debt to Book Value Verona Pharma PLC|VRNA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Verona Pharma|Quick Ratio veronapharma.com
- business earnings and investment ratios data:
VRNA - Final Profit|Projected Future Earnings Verona Pharma plc|VRNA - P/E Multiple|Future Price to Earnings Verona Pharma plc|VRNA - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Verona Pharma PLC|VRNA - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Verona Pharma|VRNA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months veronapharma.com|VRNA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Verona Pharma plc
- company sales and revenue statistics:
VRNA - Company Annual Revenue|Company Projected Revenue Verona Pharma Corp|VRNA - Price-to-Revenue Ratio|Forward P/S Multiple Verona Pharma PLC
Fundamental company analysis:Verona Pharma Corp (VRNA)
Original product of Verona Pharma Inc.

The forward P/S ratio compares the current market value of Verona Pharma plc (VRNA) with expected revenue, determining the premium investors are willing to pay per unit of future sales. This metric's dynamics react sharply to operational data regarding drug commercialization, reflecting a revision of market expectations. Analyzing the forward P/S trend allows for an assessment of the value of innovations at Verona Pharma plc (VRNA), whose growth rates depend on the success of clinical trials rather than economic cycles.

Key competitors

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|MENS: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Projected Revenue Ratio|Perrigo Company PLC - Forward Price to Sales|Price-to-Projected Revenue Ratio alvotech.com|Forward P/S Multiple Liquidia Technologies|Price-to-Projected Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Future Price to Revenue|Forward P/S Multiple MNKD (MannKind Corp)|Market Cap to Expected Sales Ratio Amphastar (AMPH)|PCRX: Forward Price-to-Revenue Multiple|SPRY - Forward P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Projected Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Projected Revenue Ratio|SCPH (scpharmaceuticals.com) - Forward P/S Multiple|TECX: Forward Price to Sales|Price-to-Projected Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Forward Price to Sales BHST|Invizyne Technologies - Forward P/S Multiple|oramed.com (ORMP) - Forward Price-to-Revenue Multiple|ENTX (enterabio.com) - Forward Price-to-Revenue Multiple|Market Cap to Projected Revenue HYFT|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP